Anti-CD7 CAR-T Cells in Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia or Lymphoma

This trial is testing a cutting-edge treatment called anti-CD7 CAR-T cell therapy for patients with relapsed or treatment-resistant T-cell acute lymphoblastic leukemia (T-ALL) — a fast-growing blood cancer. CAR-T therapy involves re-engineering a patient's own immune cells to seek and destroy cancer cells. **You may be eligible if...** - You have been diagnosed with T-cell acute lymphoblastic leukemia (T-ALL) - Your leukemia has come back after treatment or has not responded to at least one prior treatment - You are an adult (or meet the age criteria for the study) - Your cancer cells test positive for the CD7 protein **You may NOT be eligible if...** - You have uncontrolled infections, including active HIV or hepatitis - You have serious heart, lung, liver, or kidney problems - You have had prior CAR-T therapy with insufficient recovery time - You are pregnant or breastfeeding - Your cancer has spread to the brain and is not controlled Talk to your doctor to see if this trial is right for you.